(3R,4S)-4-[(1S,2R)-1,2,3-trihydroxypropyl]pyrrolidin-3-ol | 362600-27-9

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (3R,4S)-4-[(1S,2R)-1,2,3-trihydroxypropyl]pyrrolidin-3-ol
• 英文别名: (2R)-1-[(3S,4R)-4-Hydroxypyrrolidin-3-yl]propane-1,2,3-triol；(1S,2R)-1-[(3S,4R)-4-hydroxypyrrolidin-3-yl]propane-1,2,3-triol
• CAS: 362600-27-9
• 化学式: C₇H₁₅NO₄
• 分子量: 177.2
• InChiKey: JSMTUKBWIUCQOK-YTLHQDLWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.2
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  93
• 氢给体数：
  5
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  氯甲酸苄酯 、 (3R,4S)-4-[(1S,2R)-1,2,3-trihydroxypropyl]pyrrolidin-3-ol 在 sodium periodate 、 sodium tetrahydroborate 作用下， 以 N,N-二甲基乙酰胺 、 乙醇 、 水 为溶剂， 反应 3.5h， 生成 [(3R,4R)-1-benzyloxycarbonyl-4-hydroxypyrrolidin-3-yl]methanol
  参考文献：
  名称：

  7-(4-SUBSTITUTED 3- CYCLOPROPYLAMINOMETHYL-1- PYRROLIDINYL) Q UINOLONECARBOXYLIC ACID DERIVATIVE

  摘要：

  公开号：

  EP1666477B1
• 作为产物：
  描述：

  3-C-azidomethyl-3-deoxy-1,2:5,6-di-O-isopropylidene-α-D-allofuranose 在 palladium on activated charcoal Amberlite IR-120(H⁽¹⁺⁾) 、 氢气 作用下， 以 水 为溶剂， 60.0 ℃ 、1.38 MPa 条件下， 反应 19.5h， 生成 (3R,4S)-4-[(1S,2R)-1,2,3-trihydroxypropyl]pyrrolidin-3-ol
  参考文献：
  名称：

  Synthesis of 1′-aza-C-nucleosides from (3R,4R)-4-(hydroxymethyl)pyrrolidin-3-ol

  摘要：

  Pyrimidine 1'-aza-C-nucleosides are synthesised by the fusion of 5-bromouracil, 5-bromocytosine and 5-bromoisocytosine with (3R,4R)-4-(hydroxymethyl)pyrrolidin-3-ol in 40-41% yield. A homologue of 1'-aza-Psi -uridine is obtained in a Mannich reaction in 65% yield by treatment of the azasugar, paraformaldehyde and uracil. N-Alkylation of (3R,4R)-4-(hydroxymethyl)pyrrolidin-3-ol with 6-chloromethyluracil gives the 6-regioisomeric homologue. (3R,4R)-4-(Hydroxymethyl)pyrrolidin-3-ol is synthesised in 25% overall yield from diacetone-D-glucose via 3-C-(azidomethyl)-3-deoxy-D-allose which is subjected to an intramolecular reductive amino alkylation reaction to give (3R,4S)-4-[(1S,2R)-1,2,3-trihydroxypropyl]pyrrolidin-3-ol followed by Fmoc protection, oxidative cleavage of the triol group with further reduction of the obtained aldehyde and subsequent deprotection of the nitrogen atom. (C) 2001 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0040-4020(01)00920-6

文献信息

• Syntheses and bio-activities of the l-enantiomers of two potent transition state analogue inhibitors of purine nucleoside phosphorylases
  作者：Keith Clinch、Gary B. Evans、George W. J. Fleet、Richard H. Furneaux、Stephen W. Johnson、Dirk H. Lenz、Simon P. H. Mee、Peter R. Rands、Vern L. Schramm、Erika A. Taylor Ringia、Peter C. Tyler

  DOI：10.1039/b517883e

  日期：——

  enantiomers of some pharmaceuticals have revealed surprising biological activities, the L-nucleoside analogues (+)-5 x HCl and (-)-6, respectively, of D-ImmH and D-DADMe-ImmH, were prepared and their PNPase binding properties were studied. For the synthesis of compound (-)-6 suitable enzyme-based routes to the enantiomerically pure starting material (3S,4S)-4-(hydroxymethyl)pyrrolidin-3-ol [(-)-6] and its

  （1R）-1-（9-脱氮杂黄嘌呤-9-基）-1,4-二脱氧-1,4-亚氨基-L-核糖醇[（+）-5]和（3S，4S）-1-[[9 -脱氮杂黄嘌呤-9-基）甲基] -4-（羟甲基）吡咯烷-3-醇[（-）-6]是Immucillin-H（D-ImmH）和DADMe-immucillin-H（D-这些D-异构体分别是嘌呤核苷磷酸化酶（PNPases）的高亲和力过渡态类似物抑制剂，被开发为针对涉及T细胞异常活化的疾病的潜在药物。盐酸C-核苷D-ImmH [（-）-5）x HCl，现在作为抗T细胞白血病剂正在“ Fodosine”处于II期临床试验，而D-DADMe-ImmH是第二代抑制剂与目标酶具有极强的结合力，并已作为抗银屑病药物进入临床第一阶段测试。由于某些药物的对映异构体显示出令人惊讶的生物学活性，因此分别制备了D-ImmH和D-DADMe-ImmH的L-核苷类似物（+）-5 x HCl和（
• Synthesis of an aza analogue of 2-deoxy-d-ribofuranose and its homologues
  作者：Vyacheslav V Filichev、Malene Brandt、Erik B Pedersen

  DOI：10.1016/s0008-6215(01)00132-x

  日期：2001.7

  Azasugars were obtained in one-pot reactions by catalytic reduction reactions of amino group precursors in aldosugars followed by intramolecular reductive amino alkylation reactions. (3R,4S)-4-[(1S)-1,2-Dihydroxyethyl]pyrrolidin-3-ol was obtained from D-xylose by two different strategies through 3-C-cyano-3-deoxy-D-ribo-pentofuranose or 3-C-azidomethyl-3-deoxy-D-ribo-pentofuranose in 6 and 16% overall

  一锅反应中的氮杂糖是通过醛糖中氨基前体的催化还原反应，然后进行分子内还原性氨基烷基化反应而获得的。（3R，4S）-4-[（1S）-1,2-二羟乙基]吡咯烷-3-醇是通过两种不同的策略通过3-C-氰基-3-脱氧-D-核糖-戊呋喃糖从D-木糖获得的或3-C-叠氮基甲基3-脱氧-D-核糖-戊呋喃糖，总收率分别为6％和16％。在相应的Fmoc-氮杂糖中二醇基团的氧化裂解，然后脱保护，得到（3R，4R）-4-（羟甲基）吡咯烷丁-3-醇。（3R，4S）-4-[（1S，2R）-1,2,3-三羟丙基]吡咯烷-3-醇是由双丙酮-D-葡萄糖通过3-脱氧-3-C-硝基甲基-D-阿洛糖合成的总产率为7％。
• 7-(4-Substituted-3-cyclopropylaminomethyl-1 pyrrolidinyl) quinolonecarboxylic acid derivative
  申请人：Asahina Yoshikazu

  公开号：US20060281779A1

  公开（公告）日：2006-12-14

  OBJECT To provide novel quinolonecarboxylic acid compounds serving as safe, strong antibacterial agents that are effective against drug-resistant bacteria that are less susceptible to conventional antibacterial agents. SOLVING MEANS There are provided 7-(4-substituted-3-cyclopropylaminomethylpyrrolidinyl)quinolonecarboxylic acid derivatives (such as 1-cyclopropyl-7-[(3S,4S)-3-cyclopropylaminomethyl-4-fluoro-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid) that exhibit strong antibacterial activity against gram-positive bacteria, such as MRSA, PRSP and VRE, while being safe. The compounds are shown by the following general formula (I):

  目的：提供新型喹诺酮羧酸化合物，作为安全、强效的抗菌剂，对耐药菌有良好的抗菌效果，而且对传统抗菌剂的抗性较低。 解决方法：提供7-(4-取代的3-环丙氨甲基吡咯烷基)喹诺酮羧酸衍生物（例如1-环丙基-7-[(3S,4S)-3-环丙氨甲基-4-氟-1-吡咯烷基]-6-氟-1,4-二氢-8-甲氧基-4-氧代-3-喹啉羧酸），对革兰氏阳性菌（如MRSA、PRSP和VRE）表现出强效的抗菌活性，同时具有安全性。这些化合物的通用式如下（I）：
• 7- (4-substituted-3-cyclopropylaminomethyl-1-pyrrolidinyl) quinolonecarboxylic acid derivative
  申请人：Kyorin Pharmaceutical Co., Ltd.

  公开号：US08106072B2

  公开（公告）日：2012-01-31

  Object To provide novel quinolinecarboxylic acid compounds serving as safe, strong antibacterial agents that are effective against drug-resistant bacteria that are less susceptible to conventional antibacterial agents. Solving Means There are provided 7-(4-substituted-3-cyclopropylaminomethylpyrrolidinyl)quinolonecarboxylic acid derivatives (such as 1-cyclopropyl-7-[(3S,4S)-3-cyclopropylaminomethyl-4-fluoro-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid) that exhibit strong antibacterial activity against gram-positive bacteria, such as MRSA, PRSP and VRE, while being safe. The compounds are shown by the following general formula (I):

  目标：提供新型喹诺酸类化合物，作为安全、强效的抗菌剂，对耐药细菌具有有效作用，且对常规抗菌剂的敏感性较低。 解决方法：提供7-(4-取代的3-环丙氨甲基吡咯啉基)喹诺酸衍生物（例如1-环丙基-7-[(3S,4S)-3-环丙氨甲基-4-氟-1-吡咯啉基]-6-氟-1,4-二氢-8-甲氧基-4-氧代-3-喹诺酸），对革兰氏阳性菌（如MRSA、PRSP和VRE）表现出强效的抗菌活性，同时具有安全性。这些化合物由以下通式（I）表示：
• 7- (4-substituted-3-cyclopropylaminomethyl-1-pyrrolidinyl) quinolonecarboxylic acid derivative technical field
  申请人：Asahina Yoshikazu

  公开号：US20090176824A1

  公开（公告）日：2009-07-09

  Object To provide novel quinolonecarboxylic acid compounds serving as safe, strong antibacterial agents that are effective against drug-resistant bacteria that are less susceptible to conventional antibacterial agents. Solving Means There are provided 7-(4-substituted-3-cyclopropylaminomethylpyrrolidinyl)quinolonecarboxylic acid derivatives (such as 1-cyclopropyl-7-[(3S,4S)-3-cyclopropylaminomethyl-4-fluoro-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid) that exhibit strong antibacterial activity against gram-positive bacteria, such as MRSA, PRSP and VRE, while being safe. The compounds are shown by the following general formula (I):

  目标 提供新型喹诺酸类化合物，作为安全、强效的抗菌剂，对耐药菌有良好的抗菌效果，对传统抗菌剂不敏感。 解决方法 提供7-(4-取代-3-环丙氨甲基吡咯烷基)喹诺酸衍生物（如1-环丙基-7-[(3S,4S)-3-环丙氨甲基-4-氟-1-吡咯烷基]-6-氟-1,4-二氢-8-甲氧基-4-氧代-3-喹啉羧酸），对革兰阳性菌有强效的抗菌活性，如MRSA、PRSP和VRE，同时具有安全性。这些化合物的一般式如下（I）：